Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia participants to accelerate biomarker discovery. Data will be openly shared and linked with clinical and genetic information to support AI-driven research and improve diagnosis and treatment development. This initiative is part of the CLARiTI alliance and aims to deepen understanding of neurodegenerative diseases through large-scale, multi-marker blood testing.
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...
Noble Capital Markets has initiated equity research coverage on VivoPower PLC, assigning an Outperform rating and setting a price target of $10. VivoPower is a B Corp-certified global developer of powered land and data center infrastructure for AI ap...
Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...
Charles Hoskinson, the founder of Cardano, has publicly reaffirmed his commitment to the project, dispelling recent rumors about his departure. This clarification is important for Cardano investors and the crypto community as it stabilizes confidence...
